AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$HUMA

Jones Keith Anthony purchased $7K of HUMA

Jones Keith Anthony purchased 10,000 shares of Humacyte, Inc. (HUMA) at $0.69 on 2026-08-20.

Original reporting
SEC EDGAR · Jones Keith Anthony
Published Aug 21, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HUMA
Neutral
high confidence
Mentioned
$HUMA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HUMANeutralLow
01

Why it matters

The director's modest buy may be viewed positively but is unlikely to affect the stock price significantly.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical milestones for Humacyte may be the real driver of insider interest.

Relevance 4/10Novelty 4/10Timing: filing date 2026-08-21

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$HUMANeutralHigh confidence
Context

Director Jones Keith Anthony bought 10,000 shares at $0.6930, increasing his stake to 40,000 shares.

Expected impact

Minimal short‑term price movement expected.

Evidence & confidence

Purchase amount is under $10k and represents a tiny fraction of float; unlikely to move price materially.

Market effects

Sector

No immediate sector impact; insider activity is isolated to Humacyte.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Humacyte, Inc.

    Biotech firm developing tissue‑engineered vascular grafts.

  • Individual
    Jones Keith Anthony

    Director of Humacyte who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HUMA insider trading history →

Related articles

AUG 19
$HUMAMed

Humacyte (HUMA) Q2 2026 Earnings Call Transcript

Humacyte (HUMA) reported Q2 2026 product revenue of $0.4M, up from $0.1M, driven by Symvess launch. V012 Phase III trial met primary endpoint, showing 91 more catheter-free days for ATEV vs. AV fistula. Company targets Nov. 2026 sBLA filing for dialysis access, with potential 2027 launch. Cash position is $80.3M post-June equity offering. Net loss was $36.8M, with $54.4M loss for H1 2026. Management noted slower-than-expected trauma market adoption and reimbursement pressures.

fool.com3 min
AUG 19
$HUMAHighAI 9/10

Humacyte publishes Phase 3 trial results in Lancet journal

Humacyte Inc. (HUMA) published one-year Phase 3 trial results in The Lancet, showing its ATEV outperformed traditional methods for hemodialysis access in end-stage kidney disease patients. The study highlighted benefits for high-risk groups. The company plans to submit a supplemental BLA in 2H 2026 to expand Symvess's label.

investing.com2 min
AUG 19
$HUMAMedAI 8/10

A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis

Humacyte (HUMA) published one-year Phase 3 trial results in The Lancet Digital Health, showing its acellular tissue engineered vessel (ATEV) outperformed autogenous AV fistula in hemodialysis patients, especially women and men with obesity/diabetes. The company plans to submit an sBLA in H2 2026 for a second AV access indication. HUMA stock rose 21.20% on the news.

stocktitan.net2 min